Cargando…

Safety and efficacy of immune checkpoint inhibitors in advanced cancer patients with autoimmune disease: A meta-analysis

Cancer patients with autoimmune disease (AID) are usually excluded from clinical trials involving immune checkpoint inhibitors (ICIs). The available electronic databases were systematically searched from inception until July 3, 2022. We recorded the incidence of immune-related adverse events (irAEs)...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Qi, Huo, Geng-wei, Zhu, Fu-yi, Yue, Ping, Yuan, Dong-qi, Chen, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762847/
https://www.ncbi.nlm.nih.gov/pubmed/36471629
http://dx.doi.org/10.1080/21645515.2022.2145102
_version_ 1784852935655555072
author Cai, Qi
Huo, Geng-wei
Zhu, Fu-yi
Yue, Ping
Yuan, Dong-qi
Chen, Peng
author_facet Cai, Qi
Huo, Geng-wei
Zhu, Fu-yi
Yue, Ping
Yuan, Dong-qi
Chen, Peng
author_sort Cai, Qi
collection PubMed
description Cancer patients with autoimmune disease (AID) are usually excluded from clinical trials involving immune checkpoint inhibitors (ICIs). The available electronic databases were systematically searched from inception until July 3, 2022. We recorded the incidence of immune-related adverse events (irAEs), progression-free survival (PFS), and overall survival (OS) data of included studies. This meta-analysis included 14 studies comprising 11511 participants; however, only 8716 participants were treated with ICI. Therefore, the analysis was conducted on 8716 patients (769 patients with AID compared to 7947 patients without AID). The pooled risk ratio (RR) for any grade and grade ≥3 irAEs was 1.74 (95% confidence interval [CI]: 1.27-2.37) and 1.43 (95% CI: 1.10-1.88), respectively. The irAEs in the same system as that of the AID were referred to as AID-homogeneous irAEs; in the other cases, there were referred to as AID-heterogeneous irAEs. Subgroup analysis found that the higher risk of AID-homogeneous irAEs contributed to the higher risk of overall irAEs among patients with AID. The pooled hazard ratio (HR) for PFS and OS was 1.09 (95% CI: 0.96–1.24) and 1.07 (95% CI: 0.94-1.22), respectively. The results of PFS and OS subgroup analyses matched the overall results. Patients with AID had a significantly higher risk of developing any grade and ≥3 grade irAEs under ICI therapy, specifically AID-homogeneous irAEs; however, the frequency of AID-heterogeneous irAEs in patients with AID was similar to irAEs in patients without AID. No statistically significant differences in PFS and OS were observed between the two groups.
format Online
Article
Text
id pubmed-9762847
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-97628472022-12-20 Safety and efficacy of immune checkpoint inhibitors in advanced cancer patients with autoimmune disease: A meta-analysis Cai, Qi Huo, Geng-wei Zhu, Fu-yi Yue, Ping Yuan, Dong-qi Chen, Peng Hum Vaccin Immunother Immunotherapeutics – Research Article Cancer patients with autoimmune disease (AID) are usually excluded from clinical trials involving immune checkpoint inhibitors (ICIs). The available electronic databases were systematically searched from inception until July 3, 2022. We recorded the incidence of immune-related adverse events (irAEs), progression-free survival (PFS), and overall survival (OS) data of included studies. This meta-analysis included 14 studies comprising 11511 participants; however, only 8716 participants were treated with ICI. Therefore, the analysis was conducted on 8716 patients (769 patients with AID compared to 7947 patients without AID). The pooled risk ratio (RR) for any grade and grade ≥3 irAEs was 1.74 (95% confidence interval [CI]: 1.27-2.37) and 1.43 (95% CI: 1.10-1.88), respectively. The irAEs in the same system as that of the AID were referred to as AID-homogeneous irAEs; in the other cases, there were referred to as AID-heterogeneous irAEs. Subgroup analysis found that the higher risk of AID-homogeneous irAEs contributed to the higher risk of overall irAEs among patients with AID. The pooled hazard ratio (HR) for PFS and OS was 1.09 (95% CI: 0.96–1.24) and 1.07 (95% CI: 0.94-1.22), respectively. The results of PFS and OS subgroup analyses matched the overall results. Patients with AID had a significantly higher risk of developing any grade and ≥3 grade irAEs under ICI therapy, specifically AID-homogeneous irAEs; however, the frequency of AID-heterogeneous irAEs in patients with AID was similar to irAEs in patients without AID. No statistically significant differences in PFS and OS were observed between the two groups. Taylor & Francis 2022-12-05 /pmc/articles/PMC9762847/ /pubmed/36471629 http://dx.doi.org/10.1080/21645515.2022.2145102 Text en © 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Immunotherapeutics – Research Article
Cai, Qi
Huo, Geng-wei
Zhu, Fu-yi
Yue, Ping
Yuan, Dong-qi
Chen, Peng
Safety and efficacy of immune checkpoint inhibitors in advanced cancer patients with autoimmune disease: A meta-analysis
title Safety and efficacy of immune checkpoint inhibitors in advanced cancer patients with autoimmune disease: A meta-analysis
title_full Safety and efficacy of immune checkpoint inhibitors in advanced cancer patients with autoimmune disease: A meta-analysis
title_fullStr Safety and efficacy of immune checkpoint inhibitors in advanced cancer patients with autoimmune disease: A meta-analysis
title_full_unstemmed Safety and efficacy of immune checkpoint inhibitors in advanced cancer patients with autoimmune disease: A meta-analysis
title_short Safety and efficacy of immune checkpoint inhibitors in advanced cancer patients with autoimmune disease: A meta-analysis
title_sort safety and efficacy of immune checkpoint inhibitors in advanced cancer patients with autoimmune disease: a meta-analysis
topic Immunotherapeutics – Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762847/
https://www.ncbi.nlm.nih.gov/pubmed/36471629
http://dx.doi.org/10.1080/21645515.2022.2145102
work_keys_str_mv AT caiqi safetyandefficacyofimmunecheckpointinhibitorsinadvancedcancerpatientswithautoimmunediseaseametaanalysis
AT huogengwei safetyandefficacyofimmunecheckpointinhibitorsinadvancedcancerpatientswithautoimmunediseaseametaanalysis
AT zhufuyi safetyandefficacyofimmunecheckpointinhibitorsinadvancedcancerpatientswithautoimmunediseaseametaanalysis
AT yueping safetyandefficacyofimmunecheckpointinhibitorsinadvancedcancerpatientswithautoimmunediseaseametaanalysis
AT yuandongqi safetyandefficacyofimmunecheckpointinhibitorsinadvancedcancerpatientswithautoimmunediseaseametaanalysis
AT chenpeng safetyandefficacyofimmunecheckpointinhibitorsinadvancedcancerpatientswithautoimmunediseaseametaanalysis